HK1062011A1 - Selective androgen receptor modulators and methodsof use thereof - Google Patents

Selective androgen receptor modulators and methodsof use thereof

Info

Publication number
HK1062011A1
HK1062011A1 HK04104977A HK04104977A HK1062011A1 HK 1062011 A1 HK1062011 A1 HK 1062011A1 HK 04104977 A HK04104977 A HK 04104977A HK 04104977 A HK04104977 A HK 04104977A HK 1062011 A1 HK1062011 A1 HK 1062011A1
Authority
HK
Hong Kong
Prior art keywords
androgen receptor
administration
selective androgen
receptor modulator
alkyl
Prior art date
Application number
HK04104977A
Other languages
English (en)
Inventor
James Dalton
Duane D Miller
Donghua Yin
Yali He
Original Assignee
Univ Tennessee Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation
Publication of HK1062011A1 publication Critical patent/HK1062011A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
HK04104977A 2000-08-24 2004-07-08 Selective androgen receptor modulators and methodsof use thereof HK1062011A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64497000A 2000-08-24 2000-08-24
US30008301P 2001-06-25 2001-06-25
PCT/US2001/026328 WO2002016310A1 (fr) 2000-08-24 2001-08-23 Modulateurs selectifs du recepteur androgenique et procedes d'utilisation de ces derniers

Publications (1)

Publication Number Publication Date
HK1062011A1 true HK1062011A1 (en) 2004-10-15

Family

ID=26971579

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04104977A HK1062011A1 (en) 2000-08-24 2004-07-08 Selective androgen receptor modulators and methodsof use thereof
HK05103982.9A HK1072243A1 (en) 2000-08-24 2005-05-12 Selective androgen receptor modulators and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK05103982.9A HK1072243A1 (en) 2000-08-24 2005-05-12 Selective androgen receptor modulators and methods of use thereof

Country Status (21)

Country Link
US (1) US6569896B2 (fr)
EP (4) EP1401801B1 (fr)
JP (2) JP2004518617A (fr)
KR (1) KR20030061783A (fr)
CN (2) CN1230418C (fr)
AT (2) ATE344233T1 (fr)
AU (2) AU8523001A (fr)
BR (1) BR0114801A (fr)
CA (1) CA2420279C (fr)
CY (2) CY1105956T1 (fr)
DE (2) DE60124322T2 (fr)
DK (2) DK1401801T3 (fr)
EA (2) EA007101B1 (fr)
ES (2) ES2321933T3 (fr)
GE (1) GEP20053586B (fr)
HK (2) HK1062011A1 (fr)
HR (1) HRP20030118B1 (fr)
MX (1) MXPA03001632A (fr)
PT (2) PT1401801E (fr)
SI (1) SI1401801T1 (fr)
WO (1) WO2002016310A1 (fr)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7518013B2 (en) * 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) * 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US20060019931A1 (en) * 2003-10-14 2006-01-26 Dalton James T Treating bone-related disorders with selective androgen receptor modulators
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US20060004042A1 (en) * 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
BR0215115A (pt) 2001-12-06 2005-04-19 Gtx Inc Tratamento de perda muscular com moduladores de receptores de androgênio seletivos
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
BRPI0307699A2 (pt) 2002-02-07 2015-06-16 Gtx Inc Tratamento de hiperplasia benigna da próstata com sarms.
CA2476657A1 (fr) * 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Composes a substitution haloacetamide et azide et procedes d'utilisation associes
BR0308176A (pt) * 2002-02-28 2005-01-04 Univ Tennessee Res Foundation Moduladores seletivos receptores de androgênio multi-substituìdos e seus métodos de uso
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
KR101088352B1 (ko) 2002-02-28 2011-11-30 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
CA2476651A1 (fr) * 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Modulateurs irreversibles selectifs de recepteur d'androgene et procede d'utilisation associes
EP2266577B8 (fr) * 2002-02-28 2015-01-21 University Of Tennessee Research Foundation Modulateurs de récepteur sélectif d'androgène à substitutions multiples et procédé d'utilisation associés
US7741371B2 (en) * 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7022870B2 (en) * 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
WO2004035737A2 (fr) * 2002-10-15 2004-04-29 University Of Tennessee Research Foundation Modulateurs heterocycliques selectifs du recepteur des androgenes et procedes d'utilisation associes
AU2003287077B2 (en) * 2002-10-15 2007-09-20 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
CN1726020A (zh) * 2002-10-16 2006-01-25 Gtx公司 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
JP4603528B2 (ja) 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
CA2514024A1 (fr) * 2003-01-22 2004-08-05 Gtx Inc. Traitement de troubles associes au deficit en androgenes chez la femme (adif) a l'aide de modulateurs selectifs des recepteurs androgeniques (sarm)
US20040167103A1 (en) * 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
CA2528764A1 (fr) * 2003-06-13 2004-12-29 Janssen Pharmaceutica N.V. Derives de thiazoline servant de modulateurs de recepteur des androgenes selectifs (sarms)
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
CN100462353C (zh) * 2003-06-27 2009-02-18 奥赖恩公司 用作雄激素受体调节剂的丙酰胺衍生物
CA2536349A1 (fr) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated Derives de 6-cycloamino-2-quinolinone utilises comme composes modulateurs des recepteurs d'androgenes
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds
WO2005039504A2 (fr) * 2003-10-24 2005-05-06 Eisai Co., Ltd. Composes et methodes permettant de traiter les maladies et etats pathologiques lies au recepteur 2 de type toll
WO2005051298A2 (fr) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
CN1805921A (zh) * 2003-12-16 2006-07-19 Gtx公司 选择性雄激素受体调节剂的前药及其使用方法
EP1725522B1 (fr) * 2004-03-03 2014-09-10 GlaxoSmithKline LLC Derives d'aniline utilises comme modulateurs du recepteur selectif de l'androgene
WO2005090282A1 (fr) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Composes modulateurs de recepteur d'androgenes et procedes
US7288553B2 (en) * 2004-05-03 2007-10-30 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulator (SARMS)
JP2007537236A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 筋骨格の脆弱性を治療するためのベンゾニトリル誘導体
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
DK1753417T3 (da) * 2004-06-07 2012-07-23 Univ Tennessee Res Foundation Selektiv androgenreceptormodulator og medicinske anvendelser deraf
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
PL1753417T3 (pl) * 2004-06-07 2012-09-28 Univ Tennessee Res Found Selektywny modulator receptora androgenowego i jego zastosowania medyczne
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
BRPI0513020A (pt) * 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
WO2007001448A2 (fr) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Particules polymeres revetues a diffusion regulee comme vecteurs efficaces d'administration par voie orale de produits biopharmaceutiques
MX2007008334A (es) 2005-01-10 2007-09-11 Acadia Pharm Inc Derivados aminofenilo como moduladores de receptor de androgeno selectivos.
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
BRPI0609191B8 (pt) * 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
EP2425715B1 (fr) * 2005-08-31 2014-03-05 University of Tennessee Research Foundation Traitement de symptomes de troubles rénaux avec des modulateurs sélectifs de récepteurs d'androgènes
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007050554A2 (fr) * 2005-10-25 2007-05-03 The Trustees Of Columbia University In The City Of New York Identification de composes modulant l'activite des proteines du domaine phb, et compositions obtenues a partir de ces composes
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007070682A2 (fr) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology Systeme de criblage de particules
WO2008105773A2 (fr) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology Système pour l'administration ciblée d'agents thérapeutiques
CA2652280C (fr) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymeres pour particules fonctionnelles
WO2007150030A2 (fr) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Synthèse microfluidique de nanoparticules organiques
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
ES2581765T3 (es) 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
EA019849B1 (ru) * 2006-08-28 2014-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US9217129B2 (en) * 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124634A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Micelles inverses encapsulées par un polymère
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
CN101284795B (zh) * 2007-04-09 2012-04-25 中国科学院上海药物研究所 一类非甾体雄激素受体调节剂及其医学用途
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EA018611B1 (ru) * 2007-09-11 2013-09-30 ДЖиТиЭкс, ИНК. Твердые формы селективных модуляторов рецепторов андрогена
EP2644192B1 (fr) 2007-09-28 2017-05-10 Pfizer Inc Ciblage de cellules de cancer utilisant des nanoparticules
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
EP2489656A1 (fr) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Modulateurs de récepteurs androgènes sélectifs (sarm) et leurs utilisations
AU2009215843B2 (en) 2008-02-22 2011-09-08 Ellipses Pharma Ltd Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2010002075A1 (fr) * 2008-07-02 2010-01-07 Pharmacostech Co., Ltd. Procédés de préparation de dérivés d'amide
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
ME02474B (fr) 2010-05-12 2017-02-20 Radius Health Inc Schémas thérapeutiques
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012071340A1 (fr) 2010-11-23 2012-05-31 Metamagnetics Inc. Module d'antenne de taille réduite, à gain élevé, et à rendement de puissance accru
CN117736134A (zh) * 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
US20150057452A1 (en) 2012-04-04 2015-02-26 Catylix, Inc. Selective androgen receptor modulators
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
RU2510392C1 (ru) * 2012-12-21 2014-03-27 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) Сокристаллическая форма бикалутамида
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
JP2017531012A (ja) * 2014-10-16 2017-10-19 ジーティーエックス・インコーポレイテッド Ｓａｒｍを使用した泌尿器系障害の治療方法
ES2953915T3 (es) 2014-10-22 2023-11-17 Havah Therapeutics Pty Ltd Métodos para reducir la densidad mamaria mamográfica y/o el riesgo de cáncer de mama
WO2016079522A1 (fr) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Modulateurs du récepteur des androgènes et leur utilisation comme agents anticancéreux
WO2016079521A1 (fr) 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Modulateurs du récepteur des androgènes et leur utilisation comme agents anti-cancer
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US9814698B2 (en) 2015-04-21 2017-11-14 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP2018513179A (ja) 2015-04-21 2018-05-24 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンド及びその使用方法
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN108472302A (zh) 2015-10-22 2018-08-31 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ａｒ＋乳癌の治療方法
FI3565542T3 (fi) 2017-01-05 2024-06-24 Radius Pharmaceuticals Inc Rad1901-2hcl:n polymorfisia muotoja
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
WO2020243777A1 (fr) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Formulations pharmaceutiques et systèmes pour l'administration d'un agent androgène et d'un inhibiteur de l'aromatase, et procédés d'utilisation
IL301906A (en) 2020-10-08 2023-06-01 Targimmune Therapeutics Ag Immunotherapy for cancer treatment
EP4001293A1 (fr) * 2020-11-23 2022-05-25 Justus-Liebig-Universität Gießen Tétrapeptide et son utilisation
WO2022171163A1 (fr) * 2021-02-10 2022-08-18 Etern Biopharma (Shanghai) Co., Ltd. Procédés de modulation de condensats de récepteurs aux androgènes
CA3237153A1 (fr) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Conjugues lineaires cibles comprenant du polyethyleneimine et du polyethylene glycol et polyplexes comprenant ceux-ci
WO2024100040A1 (fr) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Conjugués linéaires ciblant psma comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci
WO2024100044A1 (fr) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Polyplexes d'acides nucléiques et conjugués ciblés comprenant de la polyéthylèneimine et du polyéthylène glycol
WO2024100046A1 (fr) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Conjugués linéaires ciblés comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (fr) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, procédé pour leur préparation et compositions pharmaceutiques et vétérinaires les contenant
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
EP0748220A4 (fr) 1994-01-21 1997-09-10 Sepracor Inc Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
WO1998053826A1 (fr) * 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Composes agonistes non steroidiens et leur utilisation dans le cadre de therapies a base d'hormones males
US6019957A (en) 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging

Also Published As

Publication number Publication date
CA2420279C (fr) 2011-07-19
AU2001285230C1 (en) 2008-03-13
EP1401801A1 (fr) 2004-03-31
CA2420279A1 (fr) 2002-02-28
ATE423092T1 (de) 2009-03-15
JP2004518617A (ja) 2004-06-24
WO2002016310A9 (fr) 2002-07-18
ES2321933T3 (es) 2009-06-15
HRP20030118B1 (en) 2008-06-30
JP2006306880A (ja) 2006-11-09
US20020099096A1 (en) 2002-07-25
EA007101B1 (ru) 2006-06-30
ES2275717T3 (es) 2007-06-16
PT1491524E (pt) 2009-04-16
MXPA03001632A (es) 2004-09-10
EP1401801B1 (fr) 2006-11-02
EP2284149A1 (fr) 2011-02-16
PT1401801E (pt) 2007-02-28
WO2002016310A1 (fr) 2002-02-28
EP1491524A2 (fr) 2004-12-29
EA014224B1 (ru) 2010-10-29
BR0114801A (pt) 2003-10-14
EP1491524B1 (fr) 2009-02-18
KR20030061783A (ko) 2003-07-22
DK1491524T3 (da) 2009-05-04
CN1736371B (zh) 2010-05-12
AU2001285230B2 (en) 2007-01-25
DE60137728D1 (de) 2009-04-02
DE60124322T2 (de) 2007-05-31
GEP20053586B (en) 2005-07-25
EP1705174A1 (fr) 2006-09-27
HRP20030118A2 (en) 2005-02-28
DE60124322D1 (de) 2006-12-14
EP1491524A3 (fr) 2005-04-20
EP1401801A4 (fr) 2004-08-18
CY1110459T1 (el) 2015-04-29
AU8523001A (en) 2002-03-04
EA200300283A1 (ru) 2003-08-28
HK1072243A1 (en) 2005-08-19
SI1401801T1 (sl) 2007-04-30
CN1736371A (zh) 2006-02-22
CY1105956T1 (el) 2011-04-06
CN1230418C (zh) 2005-12-07
US6569896B2 (en) 2003-05-27
EA200501269A1 (ru) 2006-02-24
DK1401801T3 (da) 2007-03-05
CN1471508A (zh) 2004-01-28
ATE344233T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
HK1062011A1 (en) Selective androgen receptor modulators and methodsof use thereof
EA200000155A3 (ru) 4-фенилпиридиновые производные
JP2010143905A (ja) 脂肪性物質およびジアミノピラゾロン誘導体を含む、ケラチン繊維の酸化染色のための組成物
JP3289900B2 (ja) メタ−アミノフェノール、ケラチン繊維の酸化染色用カップリング剤としてその使用、染色組成物および方法
JP2004511462A5 (fr)
GB1270230A (en) Method and composition for suppressing methane formation in a rumen fluid
FI945581A0 (fi) Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina
IL126110A0 (en) Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use
ES2167853T3 (es) N-aril 2-hidroxi alquilamidas.
JP2017514788A (ja) 酸化剤組成物およびｕｖ可視放射線を用いてケラチン繊維を脱色または染色するための方法
AUPR118000A0 (en) Therapeutic molecules and methods
DK0666252T3 (da) Perfluoralkylgruppebærende phenylsubstituerede alkylcarboxylsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum samt et medikament indeholdende disse
DK0821952T3 (da) Anvendelse af isoxazol- og crotonsyreamidderivater til modulering af apoptose
EP1328511A4 (fr) (e)-styryl benzylsulfones substitues destines au traitement de troubles a evolution chronique
FI945582A (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
ATE220919T1 (de) Zusammensetzungen zur minimierung des uterustrophischen effekts von tamoxifen und dessen analogen
US20060283474A1 (en) Applicator for hair products
SE9203211L (sv) Tygmjukningsmedel med fettsyra och slaeppmedel
PL317650A1 (en) Fungicidal mixture
DE3475303D1 (en) Halo((phenoxypyridyl)methyl)esters, process for their preparation and their use as insecticides
RU99120174A (ru) Гидрометильные производные 2-амино-1,2,3,4-тетрагидронафталина в качестве сердечно-сосудистого агента
UA38563A (uk) Спосіб йодування кухонної солі
RU98112830A (ru) Состав для лечения сквамозно-гиперкератотической формы рубромикоза стоп и кистей
JPS5618975A (en) Movel benzofuran derivative, and muscle relaxant containing the same
RU95114363A (ru) Производные азаспиросоединений, способ их получения, фармацевтическая композиция, средства для лечения ожирения, средства для лечения аффективных расстройств

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120823